Natera, Inc. announced that the U.S. Patent and Trademark Office has issued the company a new patent related to the testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This patent further solidifies Natera's intellectual property in precision medicine.
This new patent builds upon Natera’s extensive intellectual property estate, which includes a robust portfolio of molecular residual disease (MRD) testing patents. The patents cover both whole exome and whole genome sequencing technologies, crucial for its Signatera platform.
The expansion of Natera's patent portfolio enhances its competitive position and protects its innovative technologies in the rapidly growing field of tumor-informed MRD testing. This strategic move helps to safeguard the company's market leadership and future product development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.